We believe in curiosity

Regulatory, Market Access and Medical Affairs in Belgium - The Netherlands - Luxembourg

We bring science, authorities and business together around a common goal for the patient. Through cross-functional collaboration, we translate strategy straight into launch implementation across the BeNeLux region.

EU HTA - what you need to know

A Health Technology Assessment (HTA, benefit assessment of health technologies) is a central part of market access for innovative products as it provides the basis for successful patient access and reimbursement. Until 2025, HTA procedures across Europe have been carried out independently at national level. With Regulation (EU) 2021/2282 coming into force, the national clinical parts of the HTAs will now be gradually amended by a Joint Clinical Assessment (JCA) at European level, starting from 2025.

OUR SERVICES

We offer a better, stronger and faster way to bring your pharmaceutical and medical device technology to patients. AxTalis offers complementary Regulatory, Market Access & Medical Affairs services in a unique region. Collaborate with a creative team that combines access competence with market knowledge and medical expertise.

REGULATORY COMPLIANCE

Regulatory Compliance provides strategic and technical advice throughout the lifecycle of a healthcare solution and helps set the stage for current and future commercial success.

MEDICAL
AFFAIRS

Medical affairs has a cross-functional leadership role to help define a prioritised strategy that tackles the most important challenges and grasps the most interesting medical opportunities.

MARKET ACCESS -
HEOR

The fundamental access conditions shape your business success for years to come. We give your future success a head start by co-creating the building blocks in early dialogue with all stakeholders.

AxTalis and MAP join forces

We are delighted that AxTalis and MAP have joined forces to create a new group focussing on accelerating patient access across European markets.

This marks a significant milestone for the new group, as it strengthens the company’s position in mainland Europe, with the aim of delivering a joined up, comprehensive portfolio of services. By combining AxTalis’s geographical footprint and services alongside MAP’s proprietary membership platform and specialist consultancy expertise the group is well poised to offer enhanced services to a wider range of Biopharma and Medtech companies.

AxTalis in numbers

Clients

Projects

Teams

Let’s have a chat.

We pride ourselves to have a personal relationship with our network of stakeholders, opinion leaders and clients, and we would love to get to know you as well. Feel free to reach out for a chat.

We believe in curiosity

Regulatory, Market Access and Medical Affairs in Belgium - The Netherlands - Luxembourg

EU HTA - what you need to know